Trial Profile
A Placebo-Controlled, Double-Blind, Randomized, Proof-of-Concept Study to Evaluate the Efficacy and Tolerability of Erenumab in Patients with Trigeminal Neuralgia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Pain; Trigeminal neuralgia
- Focus Proof of concept; Therapeutic Use
- 28 Oct 2021 Status changed from recruiting to completed.
- 19 Nov 2019 Status changed from not yet recruiting to recruiting.
- 05 Aug 2019 New trial record